Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Descamps

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Journal of Bone and Joint Infection|March 3, 2020
Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to <i>Staphylococcus</i> treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in FranceA Becker, L Kreitmann, C Triffaut-Fillit, et al.
Atherosclerosis|February 18, 2014
Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project GroupMichel R Langlois, Olivier S Descamps, Arnoud van der Laarse, et al.
Atherosclerosis|December 7, 2019
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countriesUma Ramaswami, Marta Futema, Martin P Bogsrud, et al.
Atherosclerosis|September 12, 2020
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levelsKang H Zheng, Yannick Kaiser, Casper C van Olden, et al.
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
Atherosclerosis. Supplements|August 28, 2019
The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinionMaciej Banach, Eric Bruckert, Olivier S Descamps, et al.
Acta Cardiologica|September 23, 2020
Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategyOlivier S Descamps, Ernst Rietzschel, Anja Laporte, et al.
European Heart Journal|October 23, 2010
Lipoprotein(a) as a cardiovascular risk factor: current statusBørge G Nordestgaard, M John Chapman, Kausik Ray, et al.
Lancet (London, England)|February 26, 2013
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control studyPhilippa J Talmud, Sonia Shah, Ros Whittall, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Journal of Bone and Joint Infection|March 3, 2020
Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to <i>Staphylococcus</i> treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in FranceA Becker, L Kreitmann, C Triffaut-Fillit, et al.
Atherosclerosis|February 18, 2014
Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project GroupMichel R Langlois, Olivier S Descamps, Arnoud van der Laarse, et al.
Atherosclerosis|December 7, 2019
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countriesUma Ramaswami, Marta Futema, Martin P Bogsrud, et al.
Atherosclerosis|September 12, 2020
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levelsKang H Zheng, Yannick Kaiser, Casper C van Olden, et al.
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
Atherosclerosis. Supplements|August 28, 2019
The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinionMaciej Banach, Eric Bruckert, Olivier S Descamps, et al.
Acta Cardiologica|September 23, 2020
Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategyOlivier S Descamps, Ernst Rietzschel, Anja Laporte, et al.
European Heart Journal|October 23, 2010
Lipoprotein(a) as a cardiovascular risk factor: current statusBørge G Nordestgaard, M John Chapman, Kausik Ray, et al.
Lancet (London, England)|February 26, 2013
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control studyPhilippa J Talmud, Sonia Shah, Ros Whittall, et al.
Pageof 10